ARANOTE Trial Explores Darolutamide’s Role in High and Low-Volume Metastatic Prostate Cancer - Fred Saad
urotoday.com/aranote-te/vid...
Things are moving quickly. Look at those response rates. In just a few years we've improved 3x re: ADT vs double hormone blockade. And darolutamide hasn't been around very long. Researchers are already developing gen 3 ARSIs.
